Gyrus Capital
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt
Gyrus Capital explores Essential Pharma sale via Rothschild
UK-based specialty pharma group expected to be marketed off around GBP 70m EBITDA
Gyrus reaps 8.6x money from partial dss+ exit to Inflexion
Majority investment in Switzerland-headquartered management consultancy marks Inflexion Buyout Fund VI’s fifth deal
Gyrus buys majority stake in Katalist Group
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Gyrus Capital's Essential Pharma refinances, inks two deals
In parallel with the refinancing, Essential Pharma completed two M&A deals in December
GP Profile: Gyrus looks to next steps after debut pandemic fundraise
Co-founder Guy Semmens discusses the GP's first-time fundraise, its deal pipeline, and the lead-up to its next fund
Gyrus closes Investment Programme on EUR 430m
Gyrus expects the funds to be fully deployed within 12 months, with a new fundraise in 2022
Gyrus carves out PwC Italia's consulting business
Gyrus intends to expand the company's team and further broaden its product offering in Italy and internationally
Gyrus holds close for Gyrus Investment Program
Program comprises Gyrus Principal Fund and its co-investment Cortex fund; it has a €400m hard-cap
Gyrus bolsters team
Christian Wipf from GCA Altium Switzerland and Mattias Terribilini from Rothschild join the executive team
Gyrus Principal Fund to close in Q2 2021
Fund focuses on healthcare, technology and sustainability, and expects to close on its €400m hard-cap
DACH Fundraising Pipeline - Q1 2021
Unquote compiles a roundup of the most notable fundraises ongoing across the DACH market, including Capiton, Afinum, Gyrus, Cipio, and more
The Deals Pipeline
A highlight of deal processes underway and involving PE, either on the buy- or sell-side, across Europe
Gyrus completes recap for DuPont Sustainable Solutions
First realisation since the GP's establishment in 2018 sees a 60% return on invested capital for investors
Gyrus buys LivaNova heart valve business for €60m
Gyrus has also made an offer for the heart valve's French division, but a decision remains to be made
Gyrus Capital hires two
Healthcare-focused GP was launched in early 2019 by former Argos Wityu partner Guy Semmens
Gyrus announces new deal, appoints Tobin as partner
Gyrus Capital announces the buyout of Essential Pharma and adds to its team ahead of a new round of fundraising
Gyrus signs first deal with DowDuPont carve-out
Just four months after being launched, Gyrus Capital has signed the complex carve-out of DuPont Sustainable Solutions